{"id":"W2167984747","doi":"10.1111/j.1524-4733.2010.00738.x","title":"How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma","year":2010,"lang":"en","type":"article","venue":"Value in Health","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Sunitinib; Reimbursement; Medicine; Context (archaeology); Oncology; Internal medicine; Tyrosine-kinase inhibitor; Sorafenib; Renal cell carcinoma; Cabozantinib; Kidney cancer; Cancer; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01203636,0.0008518841,0.001883621,0.002967214,0.002113475,0.006258759,0.001269656,0.002328536,0.002919795],"category_scores_gemma":[0.06906155,0.0004141823,0.001792239,0.006243782,0.001752021,0.002165891,0.0009069632,0.003638034,0.0002179086],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.05885896,"about_ca_system_score_gemma":0.1015916,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9508227,"about_ca_topic_score_gemma":0.9761513,"domain_scores_codex":[0.9898928,0.005446718,0.000479098,0.0003508783,0.00289099,0.0009395637],"domain_scores_gemma":[0.9511622,0.03031024,0.002050696,0.0009053053,0.01422007,0.001351497],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.00390321,0.0003845665,0.2119389,0.003405627,0.006113676,0.001305964,0.001445952,0.1633725,0.001044674,0.1030958,0.1314963,0.3724929],"study_design_scores_gemma":[0.002241674,0.0007094307,0.3922565,0.007685416,0.009766537,0.0009386722,0.004879814,0.249843,0.002130736,0.1496983,0.1790322,0.0008177136],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.3145555,0.0637678,0.01385047,0.4471261,0.00140519,0.0005442823,0.02165513,0.0002968654,0.1367987],"genre_scores_gemma":[0.9566538,0.01447945,0.01510499,0.009245357,0.000397834,0.00005834686,0.001981832,0.00005125029,0.00202717],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.941141,"threshold_uncertainty_score":0.4270536,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.261720571965914,"score_gpt":0.4142385738600041,"score_spread":0.15251800189409,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}